Editorial: Strain-specific probiotics: enhancing children's health through targeted clinical research

A major theme emerging from the collection is the role of probiotics in modulating immune function and reducing infections in children. Several randomized controlled studies investigated Bifidobacterium longum subsp. infantis YLGB-1496 in young children, demonstrating beneficial effects on common pediatric illnesses, immune regulation, and gut microbiota composition (1,2). Improvements in respiratory symptoms, gastrointestinal health, and immune-related biomarkers suggest that early microbiota modulation may strengthen host defense during critical periods of immune maturation.These findings carry particular weight because early childhood represents a window of developmental vulnerability. Environmental exposures, feeding practices, antibiotic use, and microbial colonization patterns during this period may exert long-term health effects. The observed benefits of targeted bifidobacterial supplementation support the hypothesis that selective microbiota interventions can help optimize immune resilience.Respiratory health represented another important area of investigation. Several studies and reviews explored the relationship between probiotics and pediatric respiratory diseases, including recurrent upper respiratory tract infections (3)(4)(5). One randomized controlled trial evaluating probiotic supplementation in infants reported improvements in both respiratory and gastrointestinal outcomes, accompanied by favorable shifts in gut microbial composition and immune parameters (3).Narrative reviews also summarized accumulating evidence supporting strainspecific probiotics, particularly Lacticaseibacillus rhamnosus GG, in respiratory disease prevention (5,6). These studies contribute to the growing understanding of the gut-lung axis, the bidirectional network linking intestinal microbiota with pulmonary immune responses.The collection made important contributions to allergic disease prevention and immune modulation. Allergic disorders continue to increase among children globally, and microbiota dysbiosis has been proposed as a major contributing factor. One clinical study investigated Bifidobacterium lactis BLa80 supplementation in reducing eczema incidence and respiratory infections in early childhood, demonstrating beneficial effects on microbiota balance and immune regulation (7).Systematic and umbrella reviews evaluated current evidence regarding probiotics in atopic dermatitis prevention and management (8,9). While some strains showed encouraging preventive effects, the reviews emphasized substantial heterogeneity in study design, probiotic formulation, timing of intervention, and clinical endpoints.Gastrointestinal diseases remain among the most established applications of probiotics in pediatric medicine, and multiple articles expanded the evidence base. Acute gastroenteritis, antibiotic-associated diarrhea, and intestinal dysbiosis continue to represent major global health burdens in infants and young children.One systematic review evaluated the combined use of Saccharomyces boulardii CNCM I-745 and smectite in children with acute gastroenteritis, reporting favorable effects on symptom duration and recovery (10). Another multicenter clinical study explored probiotic co-treatment for antibiotic-associated diarrhea, demonstrating benefits in symptom control and treatment tolerance (11). Additional reviews summarized the role of probiotics in pediatric gastrointestinal disorders and necrotizing enterocolitis prevention (12)(13)(14).Several articles moved beyond traditional gastrointestinal endpoints to explore broader systemic implications of microbiota modulation. Researchers increasingly recognize that gut microbial communities influence not only digestion and immunity, but also metabolic, endocrine, and neurobehavioral pathways.A particularly noteworthy aspect of this Research Topic was the inclusion of studies investigating the microbiota-gut-brain axis and neurodevelopmental disorders. Reviews focusing on autism spectrum disorder summarized recent advances in dietary interventions, microbiota modulation, and probiotic strategies aimed at improving gastrointestinal and behavioral symptoms (15). Alterations in microbial diversity, intestinal permeability, microbial metabolites, and immune activation may contribute to autism-related pathophysiology.Another review explored the association between trans fatty acid exposure, gut microbiota dysbiosis, inflammation, and attention-deficit/hyperactivity disorder (ADHD) (16). By integrating nutritional, microbial, and neurodevelopmental perspectives, these contributions reflect the increasingly interdisciplinary nature of pediatric microbiome research.The Research Topic also addressed obesity and metabolic dysfunction in children. Several articles discussed how probiotic interventions may influence metabolic homeostasis, adiposity, inflammation, and intestinal barrier integrity (17).Beyond common pediatric conditions, the collection included studies in rare or specialized clinical settings. One systematic review explored microbiota-targeted interventions in children with Prader-Willi syndrome, highlighting emerging evidence that microbiota modulation may provide adjunctive therapeutic benefits in this challenging population (18).Another innovative contribution examined Lactiplantibacillus plantarum DSM 33464 in children with elevated blood lead levels. This randomized placebocontrolled trial suggested that probiotic supplementation may have detoxification-related potential through modulation of intestinal barrier function, microbial metabolism, and heavy metal handling (19).Several articles explored methodological and conceptual issues relevant to pediatric probiotic research, emphasizing the importance of strain characterization, genomic identification, viability assessment, dosage standardization, and long-term safety evaluation (20)(21)(22)(23). As probiotic research matures, precise taxonomic identification and mechanistic validation are becoming essential components of high-quality translational studies.Another important theme was the integration of multi-omics technologies. Many studies incorporated microbiome sequencing, metabolomic analyses, cytokine profiling, and immune biomarker assessment, allowing researchers to move beyond descriptive clinical outcomes and identify functional pathways linking probiotic interventions with host physiology.The collection also underscores the importance of developmental timing. Infancy and early childhood are periods of rapid microbial and immune maturation, during which interventions may exert disproportionately large biological effects. Several studies suggested that early-life probiotic supplementation may influence long-term immune tolerance, allergic susceptibility, and metabolic programming.Despite encouraging findings, the collection highlights persistent challenges. First, substantial heterogeneity remains across clinical trials regarding strain selection, dosing regimens, intervention duration, and outcome assessment. This variability complicates meta-analyses and limits generalizability.Second, while many studies demonstrate statistically significant improvements in surrogate biomarkers or symptom scores, clinically meaningful endpoints and long-term follow-up data remain limited. Future research should prioritize standardized outcome measures, multicenter collaborations, and adequately powered randomized controlled trials.Third, host-related factors-including baseline microbiota composition, dietary patterns, genetics, environmental exposures, delivery mode, breastfeeding status, and antibiotic history-may substantially influence probiotic responsiveness. Precision probiotic approaches tailored to individual microbial and immunological profiles may therefore represent an important future direction.Finally, regulatory and translational challenges remain. Although probiotics are widely marketed globally, the scientific rigor supporting different formulations varies considerably. This Research Topic reinforces the necessity of evidencebased clinical recommendations grounded in strain-specific data rather than generalized claims.The articles included in this Research Topic illustrate the progress occurring in pediatric microbiome and probiotic research. They highlight how strain-specific probiotic interventions may influence gastrointestinal, respiratory, allergic, metabolic, and neurodevelopmental health outcomes through complex interactions involving the microbiota, immune system, metabolism, and host physiology.At the same time, the collection emphasizes that probiotics should not be viewed as universally interchangeable therapeutic agents. Future progress will depend on rigorous strain-specific validation, mechanistic understanding, and carefully designed pediatric clinical trials.As microbiome science evolves, pediatric probiotic research is moving toward precision medicine approaches that integrate microbial ecology, immunology, nutrition, and systems biology. The studies gathered here contribute meaningfully to this transition and provide a foundation for future investigation.

Linked strains How central each strain is to this paper: a main subject, one of several organisms studied, or a passing mention. How we classify this →

Discussion

Be the first to comment.

Sign in to join the discussion.